Articles

Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasia

Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle;Department of Medicine, University of Washington, Seattle
Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle;Department of Medicine, University of Washington, Seattle
Department of Radiology, University of Washington, Seattle
Versant Medical Physics and Radiation Safety, Richland
Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle;Department of Medicine, University of Washington, Seattle
Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle;Department of Medicine, University of Washington, Seattle
Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle;Department of Medicine, University of Washington, Seattle
Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle
Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle
Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle;Department of Medicine, University of Washington, Seattle
Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle;Department of Medicine, University of Washington, Seattle
Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle;Department of Medicine, University of Washington, Seattle
Swedish Cancer Institute, Seattle, WA, USA
Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle;Department of Medicine, University of Washington, Seattle
Vol. 105 No. 6 (2020): June, 2020 https://doi.org/10.3324/haematol.2019.229492